Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy

Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology